MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jjco/hyag055

Медицинская библиотека · Japanese journal of clinical oncology · 2026

Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).

Sano Yusuke, Ozaka Masato, Aoki Shuichi, Nomura Shogo, Mitome Noriko, Fukuda Haruhiko, Mizui Takahiro, Kamei Keiko, Murakawa Masaaki, Eguchi Hidetoshi, Kawai Manabu, Shirakawa Hirofumi, Yagi Shintaro, Mizuno Nobumasa, Takahashi Amane, Takahashi Hidenori, Ikenaga Naoki, Okano Naohiro, Marubashi Shigeru, Nagakawa Yuichi, Kobayashi Shinjiro, Okazaki Taro, Harada Kazuaki, Akita Hirofumi, Otsuru Toru, Kagawa Shingo, Hirono Seiko, Seo Satoru, Arima Shiho, Gotohda Naoto, Fujii Tsutomu, Hatano Etsuro, Unno Michiaki, Ueno Makoto, Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group

СтатьяКлиническое исследование III фазыРандомизированное исследованиеПеревод в очереди

Аннотация

Neoadjuvant gemcitabine plus S-1 (GS) followed by surgery and adjuvant S-1 is the standard of care for resectable pancreatic cancer. Since ~73% of newly diagnosed pancreatic cancer patients are aged ≥70, effective treatments are strongly needed in this geriatric population. In unresectable pancreatic cancer, gemcitabine plus nab-paclitaxel (GnP) is widely used, even among geriatric patients. To evaluate the survival advantage of neoadjuvant GnP over GS for geriatric patients with resectable pancreatic cancer, an open-label randomized phase III trial (JCOG2101C) has been initiated since October 2022. A total of 400 patients will be enrolled from 28 institutions within 3 years. The primary endpoint is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCTs031220351 [https://jrct.mhlw.go.jp/latest-detail/jRCTs031220351].

Для цитирования: Sano Yusuke, Ozaka Masato, Aoki Shuichi, Nomura Shogo, Mitome Noriko, Fukuda Haruhiko, Mizui Takahiro, Kamei Keiko, Murakawa Masaaki, Eguchi Hidetoshi, Kawai Manabu, Shirakawa Hirofumi, Yagi Shintaro, Mizuno Nobumasa, Takahashi Amane, Takahashi Hidenori, Ikenaga Naoki, Okano Naohiro, Marubashi Shigeru, Nagakawa Yuichi, Kobayashi Shinjiro, Okazaki Taro, Harada Kazuaki, Akita Hirofumi, Otsuru Toru, Kagawa Shingo, Hirono Seiko, Seo Satoru, Arima Shiho, Gotohda Naoto, Fujii Tsutomu, Hatano Etsuro, Unno Michiaki, Ueno Makoto, Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).. Japanese journal of clinical oncology. 2026. DOI: 10.1093/jjco/hyag055.

Предметные рубрики MeSH

HumansGemcitabinePancreatic NeoplasmsDeoxycytidinePaclitaxelOxonic AcidTegafurAlbuminsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsAgedFemaleMale
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.